ArticleThe Journal of experimental medicine1996
A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice.
Article in The Journal of experimental medicine, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 102 citations in OpenAlex.
- Article
- Apoptotic cell death in disease-Current understanding of the NCCD 2023.Cell death and differentiation · 2023Review
- The Role of IgM Antibodies in T Cell Lymphoma Protection in a Novel Model Resembling Anaplastic Large Cell Lymphoma.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies.Signal transduction and targeted therapy · 2020Review
- Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells.Nature communications · 2020Article
- Defective FasL expression is associated with increased resistance to melanoma liver metastases and enhanced natural killer cell activity.Melanoma research · 2019Article
- TRAIL and FasL Functions in Cancer and Autoimmune Diseases: Towards an Increasing Complexity.Cancers · 2019Review
- T Cells and Regulated Cell Death: Kill or Be Killed.International review of cell and molecular biology · 2019Review
- Selective, efficient modulation of activated CD4+ αβT cells by the novel humanized antibody GZ-αβTCR targeting human αβTCR.Bone marrow transplantation · 2015Article
- The death domain of FADD is essential for embryogenesis, lymphocyte development, and proliferation.The Journal of biological chemistry · 2009Article
- Intratumor murine interleukin-12 gene therapy suppressed the growth of local and distant Ewing's sarcoma.Cancer gene therapy · 2006Article
- Opposing effects of bovine papillomavirus type 1 E6 and E7 genes on Fas-mediated apoptosis.Oncogene · 2005Article
- Article
- Evidence for selective transformation of autoreactive immature plasma cells in mice deficient in Fasl.The Journal of experimental medicine · 2004Article
- Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells.The Journal of experimental medicine · 2004Article
- Essential role for hematopoietic Fas ligand (FasL) in the suppression of melanoma lung metastasis revealed in bone marrow chimeric mice.Clinical & experimental metastasis · 2004Article
- The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer.The Journal of experimental medicine · 2003Article
- Disruption of pre-TCR expression accelerates lymphomagenesis in E2A-deficient mice.Proceedings of the National Academy of Sciences of the United States of America · 2002Article
- FADD/MORT1 regulates the pre-TCR checkpoint and can function as a tumour suppressor.The EMBO journal · 2000Article
- Oncogenic K-Ras and basic fibroblast growth factor prevent Fas-mediated apoptosis in fibroblasts through activation of mitogen-activated protein kinase.The Journal of cell biology · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Fas (CD95) and its ligand are central regulatory molecules in hematopoietic cells. Previous studies have suggested a role for Fas in the regulation of tumor progression, but Fas has not yet been conclusively identified as a tumor suppressor. Fas-deficient individuals lack malignant tumors, perhaps because of regulation by T cells. To investigate such a possibility, mice deficient in both T cells and Fas were generated, and they were found to develop severe B cell dysregulation characterized by malignant, lethal B cell lymphoma. Lymphoma arose from a monoclonal B220+CD19-CD5-CD23- B cell secreting immunoglobulin M, kappa rheumatoid factor. In contrast, animals containing alpha beta T cells, gamma delta T cells, and/or functional Fas suppressed the development of lymphoma. These data indicate that Fas functions as a tumor suppressor, and identifies roles for both alpha beta T cells and gamma delta T cells in Fas-independent tumor regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.